Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

The FDA announced a shift away from animal testing for drug approval, citing advanced alternatives like AI and organoids ...

The FDA is phasing out animal testing requirements for drug approval, embracing AI and organoid alternatives to improve safety and reduce costs ...

Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results ...

FDA Announces Plan to Phase Out Animal Testing. Will That Work? Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to go.

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate ...

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

The FDA is phasing out animal testing requirements for drug approval, embracing AI and organoid alternatives to improve safety and reduce costs ...